New guidance from the American College of Physicians (ACP) recommends hormone therapy as a first-line treatment for women experiencing menopausal vasomotor symptoms. The recommendation is based on high-certainty evidence and includes estrogen with progestogen for women with a uterus and estrogen monotherapy for those without.
Serotonin-norepinephrine reuptake inhibitors (SNRIs) are suggested as a second-line treatment for those who cannot tolerate first-line options. SSRIs, gabapentin, fezolinetant, and elinzanetant are listed as third-line treatments with lower certainty evidence. A systematic review and meta-analysis incorporating 90 trials involving peri- and postmenopausal women aged 49 to 57, primarily from North America and Europe, showed that hormone therapy, particularly at higher doses, effectively reduced vasomotor symptoms and modestly improved quality of life. Oxybutynin demonstrated efficacy in reducing symptoms and improving sleep, though evidence was low to moderate certainty. The review highlighted gaps in the evidence regarding long-term harms, variations across populations, and head-to-head comparisons of treatments. The guideline emphasizes the importance of clinicians proactively discussing menopause with patients and incorporating patient-centered outcomes into care.